Clinical trial · Observational
The Molecular Characterization of Multiple Myeloma at Relapse
NCT00639054CI-TRIAL-00020451MM-FISH/DNAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational study investigating prognostic factors in newly diagnosed and relapsed multiple myeloma patients by use of clinical data, biochemical markers (blood samples), cytogenetic markers and gene expression profiling (myeloma cells from fresh bone marrow samples). Enabling future genetic studies by establishing a biobank of bone marrow and peripheral blood samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Procedure | — | UNRESOLVED |
| Bone marrow examination | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Newly diagnosed patients
- description
- Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
- interventionNames
- Procedure: Bone marrow examination
- Procedure: Blood samples
- label
- Relapse patients
- description
- Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
- interventionNames
- Procedure: Bone marrow examination
- Procedure: Blood samples
- label
- Healthy controls
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients newly diagnosed with multiple myeloma and at the same time eligible for high dose chemotherapy and autologous stem cell transplantation * patients with multiple myeloma experiencing relapse after high dose chemotherapy and autologous stem cell transplantation Exclusion Criteria: * for newly diagnosed patients: age or comorbidity preventing high dose chemotherapy and autologous stem cell transplantation, * for all patients: age below 18, physical or psychological incapability to give an informed consent.
References
Publications (1)
- DERIVEDHermansen NE, Borup R, Andersen MK, Vangsted AJ, Clausen NT, Kristensen DL, Nielsen FC, Gimsing P. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation. Int J Lab Hematol. 2016 Jun;38(3):298-307. doi: 10.1111/ijlh.12486. Epub 2016 Mar 29. PMID 27027250